Vimarsana
Biggest News Aggregation in the World

Page 3 - Commercialization Services News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Commercialization Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Commercialization Services Today - Breaking & Trending Today

Cencora : MWI Animal Health Completes Integration with Shepherd Veterinary Software -October 16, 2023 at 02:17 pm EDT - Vimarsana News

Cencora : MWI Animal Health Completes Integration with Shepherd Veterinary Software -October 16, 2023 at 02:17 pm EDT

Integration enables veterinary clinics utilizing Shepherd's practice information management software access to MWI's AllyDVM industry-leading communications, retention and analytics tools ...

Laboratory of America : Investor Day Presentation -September 19, 2023 at 08:33 am EDT - Vimarsana News

Laboratory of America : Investor Day Presentation -September 19, 2023 at 08:33 am EDT

S E P T E M B E R 2 0 2 3 Investor Day September 14, 2023 ©2023 Laboratory...

Labcorp Announces 2023 Second Quarter Results - Vimarsana News

Labcorp Announces 2023 Second Quarter Results

Company Provides Full-Year Guidance Labcorp completed the spin-off of Fortrea on June 30, which is treated as discontinued operations in the historical...

Fortrea to Manage Clinical Trial for Sleep Apnea Drug Candidate - Vimarsana News

Fortrea to Manage Clinical Trial for Sleep Apnea Drug Candidate

Incannex has engaged Fortrea to manage the phase 2/3 clinical trial investigating IHL-42X for the treatment of obstructive sleep apnea.

Incannex Healthcare engages Fortrea to manage next clinical trial stage investigating IHL-42X for Obstructive Sleep Apnoea - Vimarsana News

Incannex Healthcare engages Fortrea to manage next clinical trial stage investigating IHL-42X for Obstructive Sleep Apnoea

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has engaged Fortrea as the contract research organisation (CRO) to manage the IND opening Phase 2/3 clinical...